News and Announcements
ChimpChange (ASX:CCA) Reports Record Quarter with Strong Customer Growth & Revenue up 36%
- Published July 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ChimpChange Limited (ASX:CCA) is Australia’s first digital banking platform, is pleased to present the company’s quarterly report on the businesses updated progress.
KEY TAKEAWAYS:
- Strongest customer growth developed during the quarter of 30,811, with 48,990 new customers added during the quarter.
- 100,000th new customer since IPO acquired during July 2017.
- Record level of quarter-on-quarter (QoQ) growth across key metrics.
- June quarter revenue up 36% QoQ along with PCO up 336%.
- Annualised Transaction Volume of US$113 million up from US$56 million.
- Revenue run-rate exceeded A$1m during the quarter.
- Well-funded from recent capital raise.
- Successful launch of new Round-up savings account feature set to boost engagement and support accelerating customer acquisition.
- Internal processing capability nearing completion which is expected to deliver improved costs and faster to market innovation of future products.
- Positive start for July 2017, and strong quarter across all metrics is expected to continue.
Ash Shilkin, Founder and Managing Director of ChimpChange, said:
“Our mission in building the ChimpChange banking platform has been to provide an experience that drives value to customers and in doing so reap value for our shareholders.
“As we continue to build out a robust digital platform packed with innovative features our customers love, we are tremendously gratified that our investments are translating into increased customer acquisitions, increased adoption, and higher usage per active adopter.
“We believe that the number of people choosing to bank with ChimpChange and trust our platform with their daily banking needs validates our investment and value proposition to both our customers and stakeholders. The key for our Company now is to continue to scale.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
